Pregabalin Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.
MFDS item code 201907582 · Approved 2019.10.30
This product's status changed to Expired on 2024.10.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive therapy for partial seizures in patients with epilepsy, effective whether secondary systemic symptoms are present or not. Additionally, it aids in the treatment of fibromyalgia. In summary, this drug is used for the relief of neuropathic pain, seizure control in epilepsy, and improvement of fibromyalgia symptoms.
This medication is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ Initial dose (mg/day) / Maximum dose (mg/day) / Dosing regimen ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as indicated under Dosing regimen. b: The supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if changes in mood or unusual behaviors occur during treatment, it should be reported to a healthcare professional immediately. Patients who are hypersensitive to this medication or have genetic issues such as lactose intolerance should not take it. Diabetic patients may require dosage adjustment for blood glucose control due to weight gain, and if symptoms of angioedema appear, the medication should be discontinued immediately. Elderly patients should be cautious of risks of falls due to dizziness or drowsiness, and vision changes may occur. Suddenly stopping this medication can lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety, so it should be tapered gradually under medical supervision. Patients with a history of drug abuse should be careful as the risk of misuse with this medication may be increased. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should use this medication cautiously due to potential risk of congestive heart failure. Caution should be taken when used in combination with opioid analgesics as it may increase the risk of central nervous system depression. In early pregnancy, there is a risk of fetal malformation, so this medication should be avoided in pregnant women, and women of childbearing age should use effective contraception. Breastfeeding women should evaluate whether to discontinue breastfeeding or the medication as it may transmit through breast milk and affect infants. This medication may cause dizziness and drowsiness, so changes in symptoms should be observed before driving or operating hazardous machinery. Severe skin reactions may occur rarely, so if symptoms such as rashes, redness, or blisters develop, treatment should be stopped immediately and a healthcare provider should be consulted. Overdose may cause confusion, drowsiness, seizures, and may require treatment such as blood dialysis if necessary. Keep out of reach of children, and do not transfer to another container for safety.
suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, pain, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, hyperesthesia, restlessness, anxiety, mood instability, emotional lability, difficulty in finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to control, apathy, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremor, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, diminished reflexes, motor abnormalities, psychomotor agitation, position-induced dizziness, hyperesthesia, burning sensation, activity tremor, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing difficulties, diplopia, indirect vision loss, visual disturbances, visual field deficits, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, changes in depth perception upon vibrations, strabismus, light sensitivity, vertigo, auditory sensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, flatulence, excessive salivation, gastroesophageal reflux disease, oral sensory decrease, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, joint pain, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urination disorders, incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, sensory disturbances, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, drowsiness, confusion, agitation, restlessness, seizures, worsening of convulsions, gastrointestinal disturbances, tinnitus, sleep disorders, skin diseases, increased BUN, bloody stools, shock, anaphylactic-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. It is advisable to maintain a storage temperature between 15 to 30 degrees Celsius for safe efficacy.
Hard capsule with light yellow upper and white lower shell filled with white powder
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 25mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.